Amicus Therapeutics Net Worth
Amicus Therapeutics Net Worth Breakdown | FOLD |
Amicus Therapeutics Net Worth Analysis
Amicus Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Amicus Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Amicus Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Amicus Therapeutics' net worth analysis. One common approach is to calculate Amicus Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Amicus Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Amicus Therapeutics' net worth. This approach calculates the present value of Amicus Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Amicus Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Amicus Therapeutics' net worth. This involves comparing Amicus Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Amicus Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Amicus Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Amicus Therapeutics' net worth research are outlined below:
| Amicus Therapeutics generated a negative expected return over the last 90 days | |
| Amicus Therapeutics has high historical volatility and very poor performance | |
| Amicus Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 528.29 M. Net Loss for the year was (56.11 M) with profit before overhead, payroll, taxes, and interest of 492.07 M. | |
| Amicus Therapeutics currently holds about 386.84 M in cash with (33.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Amicus Therapeutics Inc Announces Upcoming Q2 2025 Financial Results Conference Call ... |
Amicus Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Amicus Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Amicus Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Amicus Therapeutics Target Price Consensus
Amicus target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Amicus Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 12 | Strong Buy |
Most Amicus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Amicus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Amicus Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAmicus Therapeutics Target Price Projection
Amicus Therapeutics' current and average target prices are 6.05 and 15.82, respectively. The current price of Amicus Therapeutics is the price at which Amicus Therapeutics is currently trading. On the other hand, Amicus Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Amicus Therapeutics Market Quote on 22nd of July 2025
Target Price
Analyst Consensus On Amicus Therapeutics Target Price
Know Amicus Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Amicus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Amicus Therapeutics backward and forwards among themselves. Amicus Therapeutics' institutional investor refers to the entity that pools money to purchase Amicus Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2025-03-31 | 6.8 M | Bank Of America Corp | 2025-03-31 | 5.6 M | Jpmorgan Chase & Co | 2025-03-31 | 4.9 M | Vestal Point Capital Lp | 2025-03-31 | 4.3 M | American Century Companies Inc | 2025-03-31 | 3.9 M | Nuveen Asset Management, Llc | 2024-12-31 | 3.8 M | Assenagon Asset Management Sa | 2025-06-30 | 3.5 M | Nuveen, Llc | 2025-03-31 | 3.5 M | Northern Trust Corp | 2025-03-31 | 3.4 M | Wellington Management Company Llp | 2025-03-31 | 29.2 M | Vanguard Group Inc | 2025-03-31 | 29.1 M |
Follow Amicus Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.86 B.Market Cap |
|
Project Amicus Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.10) | (0.10) | |
| Return On Capital Employed | 0.04 | 0.04 | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (0.29) | (0.30) |
When accessing Amicus Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Amicus Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Amicus Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Amicus Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amicus Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Amicus Therapeutics' management manipulating its earnings.
Evaluate Amicus Therapeutics' management efficiency
Amicus Therapeutics has return on total asset (ROA) of 0.0395 % which means that it generated a profit of $0.0395 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1812) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.04, whereas Return On Tangible Assets are forecasted to decline to (0.10). At present, Amicus Therapeutics' Debt To Assets are projected to increase slightly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 10.74, whereas Other Assets are forecasted to decline to about 41.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.64 | 0.67 | |
| Tangible Book Value Per Share | (0.07) | (0.07) | |
| Enterprise Value Over EBITDA | 105.38 | 110.65 | |
| Price Book Value Ratio | 14.78 | 15.52 | |
| Enterprise Value Multiple | 105.38 | 110.65 | |
| Price Fair Value | 14.78 | 15.52 | |
| Enterprise Value | 3.1 B | 3.3 B |
The decision-making processes within Amicus Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 3.7341 | Revenue | Quarterly Revenue Growth 0.134 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amicus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amicus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Amicus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amicus Therapeutics Corporate Filings
F4 | 6th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 5th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 15th of May 2025 Other Reports | ViewVerify | |
| 24th of April 2025 Other Reports | ViewVerify |
Amicus Therapeutics Earnings Estimation Breakdown
The calculation of Amicus Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Amicus Therapeutics is estimated to be 0.0815 with the future projection ranging from a low of 0.07 to a high of 0.09095. Please be aware that this consensus of annual earnings estimates for Amicus Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.07 Lowest | Expected EPS | 0.09 Highest |
Amicus Therapeutics Earnings Projection Consensus
Suppose the current estimates of Amicus Therapeutics' value are higher than the current market price of the Amicus Therapeutics stock. In this case, investors may conclude that Amicus Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Amicus Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 12 | 66.53% | 0.0 | 0.0815 | -0.09 |
Amicus Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Amicus Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Amicus Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Amicus Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Amicus Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Amicus Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Amicus Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Amicus Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Amicus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-05-07 | 2025-03-31 | -0.07 | 0.03 | 0.1 | 142 | ||
2025-02-26 | 2024-12-31 | 0.0911 | 0.09 | -0.0011 | 1 | ||
2024-11-06 | 2024-09-30 | -0.01 | -0.02 | -0.01 | 100 | ||
2024-08-08 | 2024-06-30 | -0.06 | -0.05 | 0.01 | 16 | ||
2024-05-09 | 2024-03-31 | -0.07 | -0.16 | -0.09 | 128 | ||
2024-02-28 | 2023-12-31 | -0.06 | -0.11 | -0.05 | 83 | ||
2023-11-08 | 2023-09-30 | -0.08 | -0.07 | 0.01 | 12 | ||
2023-08-08 | 2023-06-30 | -0.12 | -0.15 | -0.03 | 25 | ||
2023-05-10 | 2023-03-31 | -0.15 | -0.18 | -0.03 | 20 | ||
2023-03-01 | 2022-12-31 | -0.13 | -0.19 | -0.06 | 46 | ||
2022-11-07 | 2022-09-30 | -0.19 | -0.12 | 0.07 | 36 | ||
2022-08-04 | 2022-06-30 | -0.22 | -0.21 | 0.01 | 4 | ||
2022-05-09 | 2022-03-31 | -0.25 | -0.3 | -0.05 | 20 | ||
2022-02-24 | 2021-12-31 | -0.16 | -0.29 | -0.13 | 81 | ||
2021-11-09 | 2021-09-30 | -0.17 | -0.19 | -0.02 | 11 | ||
2021-08-05 | 2021-06-30 | -0.21 | -0.19 | 0.02 | 9 | ||
2021-05-10 | 2021-03-31 | -0.23 | -0.25 | -0.02 | 8 | ||
2021-03-01 | 2020-12-31 | -0.22 | -0.27 | -0.05 | 22 | ||
2020-11-05 | 2020-09-30 | -0.22 | -0.23 | -0.01 | 4 | ||
2020-08-10 | 2020-06-30 | -0.26 | -0.2 | 0.06 | 23 | ||
2020-05-07 | 2020-03-31 | -0.28 | -0.34 | -0.06 | 21 | ||
2020-03-02 | 2019-12-31 | -0.27 | -0.35 | -0.08 | 29 | ||
2019-11-11 | 2019-09-30 | -0.32 | -0.24 | 0.08 | 25 | ||
2019-08-08 | 2019-06-30 | -0.33 | -0.36 | -0.03 | 9 | ||
2019-05-08 | 2019-03-31 | -0.31 | -0.39 | -0.08 | 25 | ||
2019-02-28 | 2018-12-31 | -0.28 | -0.41 | -0.13 | 46 | ||
2018-11-05 | 2018-09-30 | -0.28 | -0.31 | -0.03 | 10 | ||
2018-08-07 | 2018-06-30 | -0.33 | -0.33 | 0.0 | 0 | ||
2018-05-08 | 2018-03-31 | -0.36 | -0.28 | 0.08 | 22 | ||
2018-02-28 | 2017-12-31 | -0.3 | -0.41 | -0.11 | 36 | ||
2017-11-08 | 2017-09-30 | -0.31 | -0.41 | -0.1 | 32 | ||
2017-08-07 | 2017-06-30 | -0.36 | -0.34 | 0.02 | 5 | ||
2017-05-09 | 2017-03-31 | -0.36 | -0.39 | -0.03 | 8 | ||
2017-03-01 | 2016-12-31 | -0.33 | -0.42 | -0.09 | 27 | ||
2016-11-07 | 2016-09-30 | -0.31 | -0.33 | -0.02 | 6 | ||
2016-08-09 | 2016-06-30 | -0.33 | -0.4 | -0.07 | 21 | ||
2016-05-03 | 2016-03-31 | -0.34 | -0.35 | -0.01 | 2 | ||
2016-02-26 | 2015-12-31 | -0.3 | -0.36 | -0.06 | 20 | ||
2015-11-03 | 2015-09-30 | -0.25 | -0.32 | -0.07 | 28 | ||
2015-08-05 | 2015-06-30 | -0.24 | -0.26 | -0.02 | 8 | ||
2015-05-05 | 2015-03-31 | -0.2 | -0.25 | -0.05 | 25 | ||
2015-03-03 | 2014-12-31 | -0.18 | -0.24 | -0.06 | 33 | ||
2014-11-06 | 2014-09-30 | -0.21 | -0.22 | -0.01 | 4 | ||
2014-08-07 | 2014-06-30 | -0.23 | -0.22 | 0.01 | 4 | ||
2014-05-05 | 2014-03-31 | -0.24 | -0.25 | -0.01 | 4 | ||
2014-03-03 | 2013-12-31 | -0.32 | -0.18 | 0.14 | 43 | ||
2013-11-12 | 2013-09-30 | -0.34 | -0.29 | 0.05 | 14 | ||
2013-08-07 | 2013-06-30 | -0.35 | -0.31 | 0.04 | 11 | ||
2013-05-09 | 2013-03-31 | -0.33 | -0.35 | -0.02 | 6 | ||
2013-03-12 | 2012-12-31 | -0.37 | -0.2 | 0.17 | 45 | ||
2012-11-05 | 2012-09-30 | -0.24 | -0.34 | -0.1 | 41 | ||
2012-08-07 | 2012-06-30 | -0.23 | -0.2 | 0.03 | 13 | ||
2012-05-10 | 2012-03-31 | -0.35 | -0.35 | 0.0 | 0 | ||
2012-02-13 | 2011-12-31 | -0.37 | -0.25 | 0.12 | 32 | ||
2011-11-01 | 2011-09-30 | -0.33 | -0.28 | 0.05 | 15 | ||
2011-08-08 | 2011-06-30 | -0.32 | -0.37 | -0.05 | 15 | ||
2011-05-04 | 2011-03-31 | -0.35 | -0.39 | -0.04 | 11 | ||
2011-02-14 | 2010-12-31 | -0.15 | -0.48 | -0.33 | 220 | ||
2010-11-08 | 2010-09-30 | -0.49 | -0.56 | -0.07 | 14 | ||
2010-08-05 | 2010-06-30 | -0.53 | -0.41 | 0.12 | 22 | ||
2010-05-06 | 2010-03-31 | -0.58 | -0.54 | 0.04 | 6 | ||
2010-02-16 | 2009-12-31 | -0.59 | 1.45 | 2.04 | 345 | ||
2009-10-29 | 2009-09-30 | -0.68 | -0.59 | 0.09 | 13 | ||
2009-08-05 | 2009-06-30 | -0.65 | -0.6 | 0.05 | 7 | ||
2009-05-07 | 2009-03-31 | -0.64 | -0.55 | 0.09 | 14 | ||
2009-02-05 | 2008-12-31 | -0.62 | -0.63 | -0.01 | 1 | ||
2008-11-03 | 2008-09-30 | -0.47 | -0.36 | 0.11 | 23 | ||
2008-08-07 | 2008-06-30 | -0.51 | -0.41 | 0.1 | 19 | ||
2008-05-13 | 2008-03-31 | -0.38 | -0.34 | 0.04 | 10 | ||
2008-01-29 | 2007-12-31 | -0.4 | -0.53 | -0.13 | 32 | ||
2007-10-31 | 2007-09-30 | -0.46 | -0.46 | 0.0 | 0 | ||
2007-08-07 | 2007-06-30 | -0.48 | -1.37 | -0.89 | 185 |
Amicus Therapeutics Corporate Management
| Anthony Sileno | Senior Sciences | Profile | |
| David Clark | Chief Officer | Profile | |
| Patrik Esq | Global Officer | Profile | |
| Michael Keavany | Senior Business | Profile | |
| Patrik Florencio | Global VP | Profile | |
| Simon Harford | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.09) | Revenue Per Share | Quarterly Revenue Growth 0.134 | Return On Assets | Return On Equity |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.